Breast Cancer - Is
Arimidex Better Than Tamoxifen? Panel Says Arimidex Should Be
Treatment of Choice in Some Postmenopausal Women
August 1st 2006
New research shows that AstraZenecaís new breast cancer drug, Arimidex,
is better tolerated than tamoxifen, the current gold standard
treatment. The study found that significantly fewer patients in the
Arimidex groups had adverse side effects related to their treatment or
that caused them to withdraw from treatment.
Reuters reported that Arimidex also had a significantly better
risk-benefit profile, taking into account both the chance that patients
would have a recurrence of breast cancer and any side effects.
PRnewswire reports that an international panel of breast cancer
specialists confirmed value of aromatase inhibitors (AI) such as Arimdex
(anastrozole) as a treatment of hormone receptor-positive early breast
cancer in postmenopausal women.